aBLA Filing Intelligence & Biosimilar Opportunity

Hympavzi

Marstacimab-Hncq

Hemostatic Agents

Injection

Hympavzi is a subcutaneous antibody given to patients aged 12 and older to prevent bleeding episodes in hemophilia A or B without factor inhibitors. It works by inhibiting the tissue factor pathway to reduce the frequency of bleeds.

Approval Date

11-Oct-24

Data Exclusivity Expiry

11-Oct-28

Market Exclusivity Expiry

11-Oct-36

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

121

2027

182

2028

241

2029

302

2030

357

2031

414

2032

470

Molecule profile

Details & specifications

Molecule

Marstacimab-Hncq

Innovator

PFIZER

Dosage Form

Injection

Strength

150 mg/mL

Therapeutic Category

Hemostatic Agents

Usage

To prevent or reduce bleeding episodes related to hemophilia a or B

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets